Growth hormone deficiency is a congenital or acquired hormonal disorder, that is characterized by short stature due to lack of growth hormone. The disease can cause change in muscle mass, bone strengths, and cholesterol levels.
Download the sample report @ https://www.pharmaproff.com/request-sample/1076
This condition is found to be related to the mutation in POU1F1/Pit1, PROP1 GHRH and GH1 genes. Puberty is generally delayed or absent in adolescents with growth hormone deficiency.
Get the detailed analysis @ https://www.pharmaproff.com/report/growth-hormone-deficiency-therapeutics-pipeline-analysis
Other than mutation, severe head injury, brain surgery, radiation treatments, pituitary tumors, and infection can cause growth hormone deficiency. Novo Nordisk A/S is in the process of developing NNC0195-0092 as a somatotropin receptor agonist for the treatment of growth hormone deficiency.
Make enquiry before purchase @ https://www.pharmaproff.com/enquiry/1076
- The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.
- Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.
Toll-free: +1-888-778-7886 (USA/Canada)
Email: [email protected]